by David Wallace Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide deeper molecular responses and more durable disease control for some patients with high-risk essential thrombocythemia (ET). The findings were presented by Harinder Gill, MD, at the 2026 European Hematology Association Congress in Stockholm. What Did […]
The New WHO classification for Essential Thrombocythemia calls for revision of available evidences
Abstract In the 2016 revised classification of myeloproliferative neoplasms pre-fibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity, distinct from essential thrombocythemia (ET). Owing that the majority of cases falling in the pre-PMF category were previously diagnosed as ET, one may question about the need to re-evaluate the results of epidemiologic, clinical, and molecular […]
Kickboxing my way to Sunshine!
by Christine Kennedy Happy new year. I hope everyone will be in their best place this year. This disease has a depression end and numbers have a deep hold on us. Last year, physically and mentally, was my best year. Exercise Beats Exhaustion I started kickboxing. I think my body needed exercise. Giving in to […]
